Inhibition of botulinum neurotoxins interchain disulfide bond reduction prevents the peripheral neuroparalysis of botulism

Biochemical Pharmacology

Volumn 98, Issue 3, 2015, Pages 522-530

  Zanetti, Giulia ^a   Azarnia Tehran, Domenico ^a   Pirazzini, Marcon ^a   Binz, Thomas ^b   Shone, Clifford C ^c   Fillo, Silvia ^d   Lista, Florigio ^d   Rossetto, Ornella ^a   Montecucco, Cesare ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d Army Medical and Veterinary Research Center   (Italy)

Author keywords

Botulinum neurotoxins; Botulism; Ebselen; Inhibitors; Peripheral neuroparalysis; Thioredoxin system

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN B; BOTULINUM TOXIN F; CURCUMIN; EBSELEN; MYRICETIN; OXIDOREDUCTASE INHIBITOR; SYNAPTOBREVIN; SYNAPTOBREVIN 2; SYNAPTOSOMAL ASSOCIATED PROTEIN 25; SYNTAXIN; SYNTAXIN 1A; THIOREDOXIN; THIOREDOXIN REDUCTASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOTULISM; CONTROLLED STUDY; CYTOSOL; DISULFIDE BOND; FLACCID PARALYSIS; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; MALE; NERVE CELL CULTURE; NERVE ENDING; NEUROPROTECTION; NONHUMAN; PERIPHERAL PARALYSIS; PRESYNAPTIC MEMBRANE; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SKELETAL MUSCLE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CEREBELLUM; CHEMICALLY INDUCED; CHEMISTRY; COMPLICATION; DRUG EFFECTS; MOUSE; NERVE CELL; PARALYSIS;

ANIMALS; BOTULINUM TOXINS; BOTULISM; CELLS, CULTURED; CEREBELLUM; MALE; MICE; NEURONS; PARALYSIS; RATS; THIOREDOXIN-DISULFIDE REDUCTASE; THIOREDOXINS;

EID: 84946546748     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.09.023     Document Type: Article

References (67)

1. K.K. Hill, and T.J. Smith Genetic diversity within Clostridium botulinum serotypes, botulinum neurotoxin gene clusters and toxin subtypes Curr. Top. Microbiol. Immunol. 364 2013 1 20
2. O. Rossetto, M. Pirazzini, and C. Montecucco Botulinum neurotoxins: genetic, structural and mechanistic insights Nat. Rev. Microbiol. 12 2014 535 549
3. E.A. Johnson, and C. Montecucco Botulism Handb. Clin. Neurol. 91 2008 333 368
4. J.A. Coffield, N. Bakry, R.D. Zhang, J. Carlson, L.G. Gomella, and L.L. Simpson In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches J. Pharmacol. Exp. Ther. 280 1997 1489 1498
5. R. Eleopra, C. Montecucco, G. Devigili, C. Lettieri, S. Rinaldo, L. Verriello, and et al. Botulinum neurotoxin serotype D is poorly effective in humans: an in vivo electrophysiological study Clin. Neurophysiol. 124 2013 999 1004
6. S. Pellett, W.H. Tepp, J.M. Scherf, C.L. Pier, and E.A. Johnson Activity of botulinum neurotoxin type D (strain 1873) in human neurons Toxicon 101 2015 63 69
7. S.S. Arnon, R. Schechter, T.V. Inglesby, D.A. Henderson, J.G. Bartlett, M.S. Ascher, and et al. Botulinum toxin as a biological weapon: medical and public health management JAMA 285 2001 1059 1070
8. Centers for Disease Control and Prevention DoHaHS Possession, use, and transfer of select agents and toxins; biennial review. Final rule Fed. Regist. 77 2012 61083 61115
9. M. Montal Botulinum neurotoxin: a marvel of protein design Annu. Rev. Biochem. 79 2010 591 617
10. J.O. Dolly, J. Black, R.S. Williams, and J. Melling Acceptors for botulinum neurotoxin reside on motor nerve terminals and mediate its internalization Nature 307 1984 457 460
11. A. Rummel Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity Curr. Top. Microbiol. Immunol. 364 2013 61 90
12. R.A. Kammerer, and R.M. Benoit Botulinum neurotoxins: new questions arising from structural biology Trends Biochem. Sci. 39 2014 517 526
13. C. Colasante, O. Rossetto, L. Morbiato, M. Pirazzini, J. Molgo, and C. Montecucco Botulinum neurotoxin type A is internalized and translocated from small synaptic vesicles at the neuromuscular junction Mol. Neurobiol. 48 2013 120 127
14. C.B. Harper, S. Martin, T.H. Nguyen, S.J. Daniels, N.A. Lavidis, M.R. Popoff, and et al. Dynamin inhibition blocks botulinum neurotoxin type A endocytosis in neurons and delays botulism J. Biol. Chem. 286 2011 35966 35976
15. L.L. Simpson Ammonium chloride and methylamine hydrochloride antagonize clostridial neurotoxins J. Pharmacol. Exp. Ther. 225 1983 546 552
16. G. Schiavo, M. Matteoli, and C. Montecucco Neurotoxins affecting neuroexocytosis Physiol. Rev. 80 2000 717 766
17. A. Fischer, and M. Montal Molecular dissection of botulinum neurotoxin reveals interdomain chaperone function Toxicon 75 2013 101 107
18. M. Pirazzini, D.A. Tehran, O. Leka, G. Zanetti, O. Rossetto, and C. Montecucco On the translocation of botulinum and tetanus neurotoxins across the membrane of acidic intracellular compartments Biochim. Biophys. Acta (BBA) 2015 10.1016/j.bbamem.2015.08.014
19. M. Pirazzini, O. Rossetto, P. Bolognese, C.C. Shone, and C. Montecucco Double anchorage to the membrane and intact inter-chain disulfide bond are required for the low pH induced entry of tetanus and botulinum neurotoxins into neurons Cell Microbiol. 13 2011 1731 1743
20. A. Fischer, and M. Montal Crucial role of the disulfide bridge between botulinum neurotoxin light and heavy chains in protease translocation across membranes J. Biol. Chem. 282 2007 29604 29611 Epub 2007 July 31
21. A. de Paiva, B. Poulain, G.W. Lawrence, C.C. Shone, L. Tauc, and J.O. Dolly A role for the interchain disulfide or its participating thiols in the internalization of botulinum neurotoxin A revealed by a toxin derivative that binds to ecto-acceptors and inhibits transmitter release intracellularly J. Biol. Chem. 268 1993 20838 20844
22. G. Schiavo, E. Papini, G. Genna, and C. Montecucco An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin Infect. Immun. 58 1990 4136 4141
23. A. Kistner, D. Sanders, and E. Habermann Disulfide formation in reduced tetanus toxin by thioredoxin: the pharmacological role of interchain covalent and noncovalent bonds Toxicon 31 1993 1423 1434
24. G. Schiavo, F. Benfenati, B. Poulain, O. Rossetto, P. Polverino de Laureto, B.R. DasGupta, and et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin Nature 359 1992 832 835
25. G. Schiavo, O. Rossetto, S. Catsicas, P. Polverino de Laureto, B.R. DasGupta, F. Benfenati, and et al. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E J. Biol. Chem. 268 1993 23784 23787
26. T. Binz Clostridial neurotoxin light chains: devices for SNARE cleavage mediated blockade of neurotransmission Curr. Top. Microbiol. Immunol. 364 2013 139 157
27. S. Pantano, and C. Montecucco The blockade of the neurotransmitter release apparatus by botulinum neurotoxins Cell. Mol. Life Sci. 71 2014 793 811
28. M. Pirazzini, T. Azarnia, D. ehran, G. Zanetti, A. Megighian, M. Scorzeto, S. Fillo, and et al. Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins Cell Rep. 8 2014 1870 1878
29. M. Montal Redox regulation of botulinum neurotoxin toxicity: therapeutic implications Trends Mol. Med. 20 2014 602 603
30. T. Binz, S. Sikorra, and S. Mahrhold Clostridial neurotoxins: mechanism of SNARE cleavage and outlook on potential substrate specificity reengineering Toxins 2 2010 665 682
31. J. Lu, L.V. Papp, J. Fang, S. Rodriguez-Nieto, B. Zhivotovsky, and A. Holmgren Inhibition of mammalian thioredoxin reductase by some flavonoids: implications for myricetin and quercetin anticancer activity Cancer Res. 66 2006 4410 4418
32. J. Fang, J. Lu, and A. Holmgren Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity J. Biol. Chem. 280 2005 25284 25290
33. D.L. Kirkpatrick, M. Kuperus, M. Dowdeswell, N. Potier, L.J. Donald, M. Kunkel, and et al. Mechanisms of inhibition of the thioredoxin growth factor system by antitumor 2-imidazolyl disulfides Biochem. Pharmacol. 55 1998 987 994
34. A. Mukherjee, and S.G. Martin The thioredoxin system: a key target in tumour and endothelial cells Br. J. Radiol. 81 2008 Spec No 1:S57-68
35. R. Zhao, H. Masayasu, and A. Holmgren Ebselen a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant Proc. Natl. Acad. Sci. U. S. A. 99 2002 8579 8584
36. M. Pirazzini, F. Bordin, O. Rossetto, C.C. Shone, T. Binz, and C. Montecucco The thioredoxin reductase-thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals FEBS Lett. 587 2013 150 155
37. A. Rummel, S. Mahrhold, H. Bigalke, and T. Binz The HCC-domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction Mol. Microbiol. 51 2004 631 643
38. A. Rummel, T. Karnath, T. Henke, H. Bigalke, and T. Binz Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G J. Biol. Chem. 279 2004 30865 30870 Epub 2004 April 30
39. S. Bade, A. Rummel, C. Reisinger, T. Karnath, G. Ahnert-Hilger, H. Bigalke, and et al. Botulinum neurotoxin type D enables cytosolic delivery of enzymatically active cargo proteins to neurones via unfolded translocation intermediates J. Neurochem. 91 2004 1461 1472
40. C.C. Shone, and H.S. Tranter Growth of clostridia and preparation of their neurotoxins Curr. Top. Microbiol. Immunol. 195 1995 143 160
41. M. Rigoni, G. Schiavo, A.E. Weston, P. Caccin, F. Allegrini, M. Pennuto, and et al. Snake presynaptic neurotoxins with phospholipase A2 activity induce punctate swellings of neurites and exocytosis of synaptic vesicles J. Cell Sci. 117 2004 3561 3570
42. K.R. Aoki A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice Toxicon 39 2001 1815 1820
43. R.S. Broide, J. Rubino, G.S. Nicholson, M.C. Ardila, M.S. Brown, K.R. Aoki, and et al. The rat digit abduction score (DAS) assay: a physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis Toxicon 71 2013 18 24
44. S. Sun, W.H. Tepp, E.A. Johnson, and E.R. Chapman Botulinum neurotoxins B and E translocate at different rates and exhibit divergent responses to GT1b and low pH Biochemistry 51 2012 5655 5662
45. S. Sun, S. Suresh, H. Liu, W.H. Tepp, E.A. Johnson, J.M. Edwardson, and et al. Receptor binding enables botulinum neurotoxin B to sense low pH for translocation channel assembly Cell Host Microbe 10 2011 237 247
46. T. Yamaguchi, K. Sano, K. Takakura, I. Saito, Y. Shinohara, T. Asano, and et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial: Ebselen study group Stroke 29 1998 12 17
47. I. Saito, T. Asano, K. Sano, K. Takakura, H. Abe, T. Yoshimoto, and et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage Neurosurgery 42 1998 269 277
48. C. Montecucco, and M.B. Rasotto On botulinum neurotoxin variability MBio 2015 2015
49. T.J. Smith, K.K. Hill, and B.H. Raphael Historical and current perspectives on Clostridium botulinum diversity Res. Microbiol. 166 2015 290 302
50. Y. Torii, Y. Goto, M. Takahashi, S. Ishida, T. Harakawa, T. Sakamoto, and et al. Quantitative determination of biological activity of botulinum toxins utilizing compound muscle action potentials (CMAP), and comparison of neuromuscular transmission blockage and muscle flaccidity among toxins Toxicon 55 2010 407 414
51. F.r.A. Meunier, G. Lisk, D. Sesardic, and J.O. Dolly Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation Mol. Cell. Neurosci. 22 2003 454 466
52. L. Carli, C. Montecucco, and O. Rossetto Assay of diffusion of different botulinum neurotoxin type a formulations injected in the mouse leg Muscle Nerve 40 2009 374 380
53. R. Eleopra, V. Tugnoli, R. Quatrale, O. Rossetto, and C. Montecucco Different types of botulinum toxin in humans Mov. Disord. 19 Suppl. 8 2004 S53 S59
54. S. Pellett, W.H. Tepp, R.C.M. Whitemarsh, M. Bradshaw, and E.A. Johnson In vivo onset and duration of action varies for botulinum neurotoxin A subtypes 1-5 Toxicon 2015 10.1016/j.toxicon.2015.06.021
55. C.B. Shoemaker, and G.A. Oyler Persistence of Botulinum neurotoxin inactivation of nerve function Curr. Top. Microbiol. Immunol. 364 2013 179 196
56. D.M. Gill Bacterial toxins: a table of lethal amounts Microbiol. Rev. 46 1982 86 94
57. B. Thyagarajan, N. Krivitskaya, J.G. Potian, K. Hognason, C.C. Garcia, and J.J. McArdle Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a J. Pharmacol. Exp. Ther. 331 2009 361 371
58. R.P. Fagan, J.B. McLaughlin, and J.P. Middaugh Persistence of botulinum toxin in patients' serum: Alaska, 1959-2007 J. Infect. Dis. 199 2009 1029 1031
59. A.N. Sheth, P. Wiersma, D. Atrubin, V. Dubey, D. Zink, G. Skinner, and et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice Clin. Infect. Dis. 47 2008 1245 1251
60. A.F. Baker, K.N. Adab, N. Raghunand, H.H.S. Chow, S.P. Stratton, S.W. Squire, and et al. A phase IB trial of 24-hour intravenous PX-12, a thioredoxin-1 inhibitor, in patients with advanced gastrointestinal cancers Invest. New Drugs 31 2013 631 641
61. R.K. Ramanathan, J. Abbruzzese, T. Dragovich, L. Kirkpatrick, J.M. Guillen, A.F. Baker, and et al. A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination Cancer Chemother. Pharmacol. 67 2011 503 509
62. M.J. Parnham, and H. Sies The early research and development of ebselen Biochem. Pharmacol. 86 2013 1248 1253
63. M. Parnham, and H. Sies Ebselen prospective therapy for cerebral ischaemia Expert Opin. Investig. Drugs 9 2000 607 619
64. A. Goel, A.B. Kunnumakkara, and B.B. Aggarwal Curcumin as Curecumin: from kitchen to clinic Biochem. Pharmacol. 75 2008 787 809
65. E. Middleton, C. Kandaswami, and T.C. Theoharides The effects of plant flavonoids on mammalian cells:implications for inflammation, heart disease, and cancer Pharmacol. Rev. 52 2000 673 751
66. R. Koepke, J. Sobel, and S.S. Arnon Global occurrence of infant botulism, 1976-2006 Pediatrics 122 2008 e73 e82
67. S.S. Arnon Infant botulism Annu. Rev. Med. 31 1980 541 560